Tag Archives: Zepbound

ADA 2026 Key Press Releases (June 5)

On the first day of the ADA 2026 conference, six cardiometabolic-related news items have been observed from Tandem, Veru, Gan & Lee, Cigna, Bayer, and Structure Therapeutics. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

Kailera Files IPO; Diamyd Data Disappoints; Insilico and Lilly Partner for AI Drug Discovery; EMA Approves Bayer’s Kerendia for HFpEF; Gan & Lee QW Insulin; Roche Ph1 CAD Study; Lilly Ph3 TOGETHER-PsA Results

A series of cardiometabolic-related news items has been observed from Kailera Therapeutics, Diamyd Medical, Insilico, Bayer, Gan & Lee Pharmaceuticals, Roche, and Lilly. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Structure’s Topline Ph2 Aleniglipron Data; Lilly Launches Zepbound KwikPen; Positive Topline Ph3 Finerenone FIND-CKD Results

Three cardiometabolic-related news items have been observed: Structure Therapeutics announced updated results from its aleniglipron Ph2 obesity ACCESS trials (view press release; view slides); Lilly announced Zepbound KwikPen is now available for cash-pay patients via LillyDirect and retail pharmacies (view press release); and Bayer announced positive topline results from the Ph3 finerenone FIND-CKD study in non-T2DM CKD (view press release). Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo and Hims Take Another Turn at a Partnership; AbbVie Reports Topline Ph1 Amylin Data; Regeneron & Hansoh Share Ph3 Olatorepatide China Results; Lilly Releases Statement on CMS Obesity BALANCE Model; Zepbound KwikPen Available on Amazon; Veru Enrolls First Patient in Ph2b PLATEAU Study; Sequel Expands AID Launch 

A series of cardiometabolic-related news items has been observed from Novo Nordisk/Hims & Hers, AbbVie, Regeneron Pharmaceuticals/Hansoh, Lilly, Amazon, Veru, and Sequel Med Tech. Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here